Human Metabolome Technologies Inc

Human Metabolome Technologies Inc maintains a strong liquidity position with a current ratio of 4.14 and cash and equivalents of ¥1.56 billion, representing 65.8% of total assets. The company's debt-to-equity ratio is 0.06, indicating a conservative capital structure with minimal leverage. Free cash flow of ¥123.1 million and operating cash flow of ¥373.5 million support operational flexibility and reinvestment capacity. Profitability metrics show a return on equity of 13.43% and return on assets of 10.8%, outperforming the median for the Biotechnology & Medical Research industry. Gross margin of 63.3% (¥921.7 million gross profit on ¥1.46 billion revenue) reflects efficient cost management in its metabolomics analysis and biomarker development services. The company operates in two segments: Metabolome Analysis and Biomarker. Revenue concentration data is not disclosed, but the dual-segment model suggests diversification across service offerings and R&D activities. The Metabolome Analysis segment provides analysis services, while the Biomarker segment focuses on biomarker exploration and diagnostic development. Revenue growth is not explicitly forecasted in the outlook, but the company's operating income of ¥278.3 million and net income of ¥256.4 million indicate stable performance. Capital expenditures of -¥148.7 million suggest asset disposals or non-cash adjustments, which may reflect strategic reallocation of resources. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and high cash reserves reduce financial distress risk. No dilution pressure is currently evident, as shares outstanding remain unchanged between basic and diluted counts. Recent financial filings and transcripts do not disclose material events affecting operations or strategy. The company's focus on CE-MS technology and diagnostic development remains consistent with its disclosed business model.